Prosecution Insights
Last updated: November 04, 2026

Sirion Biotech GmbH

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Sirion Biotech GmbH has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit, which centralizes the company's prosecution strategy. With only one matter pending, the applicant can focus their resources on addressing the specific concerns raised by the USPTO in this case.

The busiest examiner, KINSEY WHITE, NICOLE ERIN, handles the 1 pending office action. Since this examiner is the only one currently reviewing the company's applications, their individual preferences and interpretations will be the deciding factor in the prosecution's success. The absence of other pending actions means there is no examiner diversity to mitigate the impact of a single negative finding.

The concentration of the workload within a single art unit allows for a more focused analysis of the relevant prior art and examination trends. Practitioners can concentrate their efforts on the specific requirements of KINSEY WHITE, NICOLE ERIN without the need to manage multiple sets of examiner expectations. This streamlined approach is well-suited for resolving the sole pending action in the Biotechnology & Pharmaceuticals sector.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KINSEY WHITE, NICOLE ERIN 1 58.1% +16.5%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18887203 RETROVIRAL TRANSDUCTION USING POLOXAMERS KINSEY WHITE, NICOLE ERIN —

Top Art Units

Art UnitApps
1672 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18887203 RETROVIRAL TRANSDUCTION USING POLOXAMERS KINSEY WHITE, NICOLE ERIN 1672 DP Non-Final OA — Pending Sep 17, 2024

Managing Sirion Biotech GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Sirion Biotech GmbH have?

Sirion Biotech GmbH has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Sirion Biotech GmbH applications?

Nicole Erin Kinsey White has the most, with 1 of Sirion Biotech GmbH's pending office actions.

What technology area are Sirion Biotech GmbH's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month